L

Leap Therapeutics
D

LPTX

0.47700
USD
-0.01
(-1.39%)
مغلق
حجم التداول
1,881
الربح لكل سهم
-1
العائد الربحي
-
P/E
-0
حجم السوق
18,277,637
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CLDX
    -0.140
    (-0.62%)
    22.450 USD
    L
    LPCN
    -0.15000
    (-4.27%)
    3.36000 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    المزيد
الأخبار
المقالات

العنوان: Leap Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .